Inhibrx Biosciences, Inc. also files under INXB; those filings are included. Filings under INBX by Inhibrx, Inc. (CIK 0001739614) from Aug 21, 2020 to May 30, 2024 belong to a different issuer and are not shown.
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Forsyth Douglas | Director | Buy(P) | 3K | $114.65 | $287K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 7K | $100.64 | $665K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 1K | $107.12 | $118K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 500 | $108.24 | $54K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 1K | $111.88 | $136K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 10K | $112.28 | $1.1M |
| Sep 8, 2026 | Kayyem Jon Faiz | Director | Buy(P) | 5K | $113.52 | $568K |
| Sep 8, 2026 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 6K | $99.29 | $585K |
| Jun 3, 2026 | Vuori Kristiina MD | Director | Grant(A) | 15K | — | $0 |
| Jun 3, 2026 | Forsyth Douglas | Director | Grant(A) | 15K | — | $0 |
| Jun 3, 2026 | Manhard Kimberly | Director | Grant(A) | 15K | — | $0 |
| Jun 3, 2026 | Kayyem Jon Faiz | Director | Grant(A) | 15K | — | $0 |
| Apr 24, 2026 | Matly David | President | Grant(A) | 50K | — | $0 |
| Oct 7, 2025 | Viking Global Opportunities Parent GP LLC | 10% Owner | Sell(S) | 309K | $32.25 | $10.0M |
| Oct 7, 2025 | Viking Global Opportunities Parent GP LLC | 10% Owner | Sell(S) | 16K | $32.25 | $526K |
| Oct 7, 2025 | Viking Global Opportunities Parent GP LLC | 10% Owner | Sell(S) | 25K | $32.25 | $808K |
| May 28, 2025 | Manhard Kimberly | Director | Grant(A) | 15K | — | $0 |
| May 28, 2025 | Forsyth Douglas | Director | Grant(A) | 15K | — | $0 |
| May 28, 2025 | Kayyem Jon Faiz | Director | Grant(A) | 15K | — | $0 |
| May 28, 2025 | Vuori Kristiina MD | Director | Grant(A) | 15K | — | $0 |
| Apr 1, 2025 | Deck Kelly | Chief Financial Officer | Grant(A) | 15K | — | $0 |
| Apr 1, 2025 | Matly David | President | Grant(A) | 50K | — | $0 |
| Mar 27, 2025 | Kayyem Jon Faiz | Director | Gift(G) | 90K | — | $0 |
| Dec 16, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 250K | — | $0 |
| Dec 16, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 250K | — | $0 |
| Dec 16, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 500K | — | $0 |
| Dec 6, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 52K | — | $0 |
| Nov 20, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 19K | $14.19 | $266K |
| Nov 20, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 19K | $14.19 | $266K |
| Nov 19, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 35K | $14.23 | $496K |
| Nov 19, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 35K | $14.23 | $496K |
| Oct 3, 2024 | Vuori Kristiina MD | Director | Buy(P) | 7K | $15.00 | $100K |
| Sep 16, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 13K | $17.13 | $223K |
| Sep 12, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 27K | $15.05 | $406K |
| Sep 11, 2024 | Vuori Kristiina MD | Director | Buy(P) | 6K | $15.07 | $97K |
| Sep 10, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 9K | $15.19 | $129K |
| Sep 10, 2024 | Vuori Kristiina MD | Director | Buy(P) | 179 | $15.00 | $3K |
| Sep 9, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 10K | $15.21 | $144K |
| Sep 6, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 26K | $15.29 | $398K |
| Sep 3, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 15K | $15.66 | $239K |
| Sep 3, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 5K | $16.31 | $77K |
| Aug 30, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 10K | $14.02 | $140K |
| Aug 29, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 10K | $14.03 | $140K |
| Aug 29, 2024 | Vuori Kristiina MD | Director | Buy(P) | 7K | $14.00 | $100K |
| Aug 28, 2024 | Manhard Kimberly | Director | Buy(P) | 10K | $13.98 | $140K |
| Aug 23, 2024 | Forsyth Douglas | Director | Buy(P) | 60K | $14.07 | $842K |
| Aug 22, 2024 | Forsyth Douglas | Director | Buy(P) | 15K | $12.89 | $196K |
| Aug 21, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 13K | $12.93 | $167K |
| Aug 20, 2024 | Lappe Mark | Chief Executive Officer, Director | Buy(P) | 27K | $12.97 | $351K |
| Jun 24, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 10K | — | $0 |
| Jun 24, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 89K | — | $0 |
| Jun 24, 2024 | Kayyem Jon Faiz | Director | Gift(G) | 10K | — | $0 |
| Jun 5, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 8K | $17.89 | $148K |
| Jun 5, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 49K | $17.23 | $849K |
| Jun 4, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 24K | $18.24 | $433K |
| Jun 4, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 65K | $17.44 | $1.1M |
| Jun 3, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 47K | $16.61 | $777K |
| Jun 3, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 81K | $17.90 | $1.4M |
| May 31, 2024 | Kayyem Jon Faiz | Director | Buy(P) | 70K | $16.14 | $1.1M |
| May 30, 2024 | Manhard Kimberly | Director | Grant(A) | 30K | — | $0 |
| May 30, 2024 | Eckelman Brendan P. | Chief Scientific Officer | Grant(A) | 175K | — | $0 |
| May 30, 2024 | Vuori Kristiina MD | Director | Grant(A) | 30K | — | $0 |
| May 30, 2024 | Kayyem Jon Faiz | Director | Grant(A) | 30K | — | $0 |
| May 30, 2024 | Deck Kelly | Chief Financial Officer | Grant(A) | 175K | — | $0 |
| May 30, 2024 | Forsyth Douglas | Director | Grant(A) | 30K | — | $0 |
| May 30, 2024 | Lappe Mark | Chief Executive Officer, Director | Grant(A) | 300K | — | $0 |
| May 29, 2024 | Eckelman Brendan P. | Chief Scientific Officer | Grant(A) | 40K | — | — |
| May 29, 2024 | Eckelman Brendan P. | Chief Scientific Officer | Grant(A) | 434K | — | — |
| May 29, 2024 | Kayyem Jon Faiz | Director | Grant(A) | 6K | — | — |
| May 29, 2024 | Inhibrx, Inc. | 10% Owner | Other(J) | 13.3M | — | — |
| May 29, 2024 | Kayyem Jon Faiz | Director | Grant(A) | 806K | — | — |
| May 29, 2024 | Lappe Mark | Chief Executive Officer, Director | Grant(A) | 622K | — | — |
| May 29, 2024 | Lappe Mark | Chief Executive Officer, Director | Grant(A) | 125K | — | — |
| May 29, 2024 | Lappe Mark | Chief Executive Officer, Director | Grant(A) | 15K | — | — |
| May 29, 2024 | Kayyem Jon Faiz | Director | Grant(A) | 6K | — | — |
| May 29, 2024 | Forsyth Douglas | Director | Grant(A) | 150K | — | — |
| May 29, 2024 | Eckelman Brendan P. | Chief Scientific Officer | Grant(A) | 40K | — | — |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Issuer: Inhibrx Biosciences, Inc., SEC CIK 0002007919. The symbol on a Form 4 is typed by the filer, so this page follows the issuer with the newest filing under INBX and shows every filing by that issuer (also filed as INXB). Earlier filings under the same symbol by another issuer are left out.
Coverage: Form 4 filings indexed 2006-01-02 → 2026-09-09. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).
Connected pages for INBX